Form 4: BioLargo Director Dennis E. Marshall Acquires Options to Purchase Common Stock

Director Dennis E. Marshall acquired options to purchase common stock in BioLargo, Inc. as compensation for services and to replace previously expired options.

Summary

• On March 28, 2024, Dennis E. Marshall, a director of BioLargo, Inc., acquired an option to purchase 64,176 shares of common stock at an exercise price of $0.35, replacing a previously expired option.
• The expired option was for 52,536 shares and expired due to a discrepancy between the original exercise price and the current stock price.
• On March 31, 2024, Marshall acquired another option to purchase 53,571 shares of common stock at an exercise price of $0.35 as payment for $18,750 in fees for board of directors services.
• Following these transactions, Marshall directly owns options to purchase 4,217,256 shares of BioLargo common stock.

Sentiment

Score: 6

Explanation: The sentiment is neutral. The document simply reports the acquisition of stock options by a director, which is a routine event. The replacement of expired options is a slightly positive sign, but overall, the impact is not significantly positive or negative.

Positives

• The granting of options to a director can align their interests with those of the shareholders.
• The options granted as compensation for board services can help conserve the company's cash.

Industry Context

Option grants to directors are a common practice in publicly traded companies as a form of compensation and to align their interests with shareholders.

Comparison to Industry Standards

• Comparing BioLargo's director compensation structure to similar small-cap companies in the environmental technology sector would provide a benchmark for assessing the reasonableness of these option grants.
• Companies like OriginClear or Aqua Metals, though not directly comparable, offer insights into equity-based compensation practices within related industries.
• Analyzing the ratio of equity compensation to cash compensation for directors in these companies can help determine if BioLargo's approach is aligned with industry norms.

Related Party Transactions

• The option grant to Dennis E. Marshall is a related party transaction as he is a director of BioLargo, Inc.

Stakeholder Impact

• Shareholders may view the option grants as a way to align the director's interests with the company's performance.
• The use of options as compensation can conserve the company's cash, which may be beneficial to creditors and other stakeholders.

Key Dates